What is AIGEN Sciences?
Founded in 2021, AIGEN Sciences Inc. operates at the intersection of computational biology and medicinal chemistry. The company has developed a specialized AI platform designed to streamline the discovery of high-potency drugs. By focusing on cellular-level activity, the platform enables researchers to identify candidates that maximize therapeutic efficacy while minimizing adverse side effects. This approach is particularly vital in the current landscape of precision medicine, where the demand for safer, more targeted treatments is at an all-time high. Headquartered in South Korea, the company is rapidly establishing itself as a key player in the global biotech ecosystem, bridging the gap between digital innovation and clinical application.
How much funding has AIGEN Sciences raised?
AIGEN Sciences has raised a total of $8.8M across 1 funding round:
Series A
$8.8M
Series A (2024): $8.8M with participation from Partners Investment, Premier Partners, and Quad Investment Management
Key Investors in AIGEN Sciences
Partners Investment
A South Korean private equity and venture capital firm that specializes in supporting start-ups and buyouts across diverse sectors including biotechnology and healthcare.
Premier Partners
A firm providing comprehensive digital infrastructure and hosting solutions, supporting the growth of technology-driven enterprises through robust server and domain management services.
Quad Investment Management
An independent asset management firm overseeing significant equity assets, known for its focus on long-term growth and providing superior portfolio management services to institutional and individual clients.
What's next for AIGEN Sciences?
With the successful closure of this Series A round, AIGEN Sciences is poised to transition from a development-focused entity to a scaling enterprise. The strategic roadmap likely includes the expansion of its internal pipeline and the potential for collaborative partnerships with global pharmaceutical giants. By utilizing the $8.8M in new capital, the company aims to validate its platform across a broader range of disease targets, further reducing the time and cost associated with preclinical drug development. As the firm continues to refine its AI-driven methodology, it remains a critical entity to watch within the rapidly evolving landscape of AI-enabled biotechnology and pharmaceutical innovation.
See full AIGEN Sciences company page
